Held in Boston from June 16–19, BIO International Convention 2025 confirmed its position as the largest and most influential gathering in the biotech industry. With over 20,000 attendees, 1,100+ speakers, and a packed agenda of sessions and meetings, the event brought together the full spectrum of the global life sciences ecosystem — from emerging biotech startups to large pharma, investors, and technology providers.
The scale of the event was matched by the diversity and relevance of its exhibitors. The exhibition floor featured a strong mix of companies across drug development, manufacturing, AI-driven platforms, and advanced therapies, alongside international pavilions showcasing innovation from key global markets. Dedicated areas focused on AI and machine learning in drug discovery, reflecting the growing role of technology in accelerating R&D and reshaping the industry.
Networking remained at the core of BIO, with more than 60,000 partnering meetings taking place throughout the event. The structured partnering system enabled highly targeted interactions, making it one of the most efficient environments for business development, fundraising discussions, and strategic collaborations.
Across sessions and conversations, several themes clearly stood out: the acceleration of AI in drug discovery, continued momentum in cell and gene therapies, and strong focus on oncology and precision medicine. The broader theme, “The world can’t wait,” was reflected in discussions around speed, innovation, and the need for stronger global collaboration in addressing both chronic and emerging health challenges.
BIO International Convention 2025 delivered not just scale, but substance — combining global reach, high-value networking, and a clear view into the technologies and partnerships shaping the future of biotech.
